Securian Asset Management Inc. Has $8.08 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Securian Asset Management Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 2.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 304,576 shares of the biopharmaceutical company’s stock after selling 8,839 shares during the quarter. Securian Asset Management Inc.’s holdings in Pfizer were worth $8,080,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the 4th quarter valued at $28,000. Gladius Capital Management LP raised its stake in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the period. Finally, Noble Wealth Management PBC bought a new stake in Pfizer in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on PFE shares. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Bank of America restated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reiterated a “buy” rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday, February 10th. Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Finally, Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

Shares of PFE stock opened at $26.00 on Wednesday. The business’s 50-day moving average price is $26.29 and its 200-day moving average price is $27.19. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The firm has a market capitalization of $147.33 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the firm posted $0.10 earnings per share. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.62%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend was Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.